NY-CELONIS
14.5.2024 08:01:35 CEST | Business Wire | Press release
Celonis, the global leader in Process Mining, announced today that it has been named a Leader in the Gartner Magic Quadrant for Process Mining Platforms for the second time since the category's inception last year. Celonis was evaluated and placed in the Leaders’ Quadrant, being positioned highest on the Ability to Execute axis and advancing to the furthest spot on the Completeness of Vision axis once again.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513067064/en/
Celonis is a Leader in the 2024 Gartner Magic Quadrant for Process Mining Platforms, placed highest on the Ability to Execute and highest on Completeness of Vision. (Graphic: Business Wire)
“The pace of change keeps accelerating - new technologies keep emerging, customer expectations keep rising, and the need for greater efficiency keeps increasing. To succeed, organizations need solutions that help them address all these demands, and most importantly create meaningful value,” said Alex Rinke, co-CEO and co-founder of Celonis. “Celonis gives companies a common language for how their business runs and provides the context to enable technologies like AI and automation to become effective. For us, being named a Leader for the second consecutive year in the Gartner Magic Quadrant for Process Mining Platforms reinforces our commitment to make processes work for people, companies and the planet. We are proud to receive this recognition and will continue to build the future of process intelligence together with our customers, partners and fellow Celonauts who have embraced our vision and keep pushing process mining to realize its full potential.”
“Process mining has become an essential enterprise solution for adapting to an uncertain world and driving transformation at speed and scale,” said Daniel de Rooij, SVP Digital Transformation and CIO Hygiene at Reckitt, a global consumer products company with well-known brands such as Finish dishwasher tablets, Lysol disinfectant, and Nurofen painkillers. “With advancements like object-centric process mining and the Process Intelligence Graph, Celonis’ platform provides us with the unique process intelligence that we need to optimize IT operations, deliver value to the business faster, and drive disruptive innovation with emerging technologies like generative AI.”
Celonis enables customers to identify and capture hidden value, empower their people with actionable insights, and help them more effectively leverage technologies like AI and automation to optimize their processes. At the core of the Celonis Platform is the Process Intelligence Graph (PI Graph), an extensible digital twin of the business based on a standardized, object-centric data model. This twin is system-agnostic and without bias. The PI Graph adds business context to this process digital twin with out-of-the-box KPI definitions and improvement opportunities, such as how delivery blocks impact on-time delivery rate. Sitting at the heart of the Celonis platform, the PI Graph allows us to create capabilities that embed AI in ready-to-use solutions. For example, the Process Copilot chatbot turns natural language requests into process insights, and the AI-powered Duplicate Checker App helps keep customers from paying invoices twice. Using our Machine Learning (ML) Workbench customers and partners can create their own AI solutions in Celonis or feed data into their existing AI tools using our Intelligence API.
The platform also provides advanced process modeling functionality. In 2023, Celonis acquired Symbio, a provider of AI-driven Business Process Management (BPM) software. The integration of Symbio’s capabilities into the Celonis platform enables customers to not only mine their processes and identify value opportunities, but also design their ideal process using a modern, AI-assisted process modeling solution. Customers can also ensure their processes stay on the straight and narrow with the Process Adherence Manager and track the business impact of their process improvement work with the Transformation Hub.
Notes to editors
The 2024 Gartner Magic Quadrant on Process Mining Platforms is available here.
Find more information on Process Mining and the Celonis Process Intelligence Platform here.
Gartner, Magic Quadrant for Process Mining Platforms, Marc Kerremans, David Sudgen, Nick Duffy, 29 April 2024
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Celonis
Since 2011, Celonis has helped thousands of the world’s largest and most esteemed companies yield immediate cash impact, radically improve customer experience, and reduce carbon emissions. Its Process Intelligence platform uses industry-leading process mining technology and AI to present companies with a living digital twin of their end-to-end processes. For the first time, everyone in an organization has a common language for how the business runs, visibility into where value is hiding, and the ability to capture it. Celonis is headquartered in Munich, Germany and New York City, USA with more than 20 offices worldwide.
© 2024 Celonis SE. All rights reserved. Celonis and the Celonis “droplet” logo are trademarks or registered trademarks of Celonis SE in Germany and other jurisdictions. All other product and company names are trademarks or registered trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513067064/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
